Natera Inc (NTRA)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Genetics Diagnosticssrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 13/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 4.58% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- ESMO 2026 Presentations Deepen the Evidence Base for Natera’s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology
- Natera’s Signatera™ MRD Test Named to TIME’s List of the Best Inventions of 2026
- Natera Gains 118.1% in a Year: What's Driving the Rally?
- How FDA Breakthrough Status For Natera’s Multi‑Cancer Test (NTRA) Has Changed Its Investment Story
- Natera (NTRA) Stock May Be 33% Below Fair Value Despite FDA Breakthrough News
- Natera (NTRA) Could Be 33% Undervalued Following FDA Breakthrough Device Designation
- Why Natera (NTRA) Stock Is Up Today
- Natera Receives FDA Breakthrough Device Designation for Multi-Cancer Early Detection Blood Test
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Natera Inc.
Full NTRA Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.